Association between prediagnostic leukocyte telomere length and breast cancer risk: the Singapore Chinese Health Study.
Biomarkers
Blood leukocytes
Breast cancer
Prospective cohort study
Risk factors
Telomere length
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
17 04 2019
17 04 2019
Historique:
received:
28
09
2018
accepted:
27
03
2019
entrez:
19
4
2019
pubmed:
19
4
2019
medline:
10
1
2020
Statut:
epublish
Résumé
Telomeres and telomerase play key roles in the chromosomal maintenance and stability. Recent epidemiological studies have shown that longer telomeres are associated with increased risk of several cancer types. However, epidemiological data for telomere length and risk of breast cancer are sparse. We prospectively studied the association between telomere length and risk of breast cancer in 14,305 middle-aged or older Chinese women of the Singapore Chinese Health Study including 442 incident breast cancer cases after 12.3 years of follow-up. Relative telomere length in peripheral blood leukocytes was quantified using a validated monochrome multiple quantitative polymerase chain reaction method. The Cox proportional hazard regression method was used to estimate hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) for breast cancer associated with longer telomeres after adjustment for potential confounders. Longer telomeres were significantly associated with higher risk of breast cancer in a dose-dependent manner (P The findings of the present study support the hypothesis that longer telomeres may be a risk factor for breast cancer. Telomere length in peripheral blood leukocytes may be developed as a biomarker for breast cancer risk prediction.
Sections du résumé
BACKGROUND
Telomeres and telomerase play key roles in the chromosomal maintenance and stability. Recent epidemiological studies have shown that longer telomeres are associated with increased risk of several cancer types. However, epidemiological data for telomere length and risk of breast cancer are sparse.
METHODS
We prospectively studied the association between telomere length and risk of breast cancer in 14,305 middle-aged or older Chinese women of the Singapore Chinese Health Study including 442 incident breast cancer cases after 12.3 years of follow-up. Relative telomere length in peripheral blood leukocytes was quantified using a validated monochrome multiple quantitative polymerase chain reaction method. The Cox proportional hazard regression method was used to estimate hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) for breast cancer associated with longer telomeres after adjustment for potential confounders.
RESULTS
Longer telomeres were significantly associated with higher risk of breast cancer in a dose-dependent manner (P
CONCLUSIONS
The findings of the present study support the hypothesis that longer telomeres may be a risk factor for breast cancer. Telomere length in peripheral blood leukocytes may be developed as a biomarker for breast cancer risk prediction.
Identifiants
pubmed: 30995937
doi: 10.1186/s13058-019-1133-0
pii: 10.1186/s13058-019-1133-0
pmc: PMC6471852
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Subventions
Organisme : NCI NIH HHS
ID : T32 CA186873
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA144034
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA182876
Pays : United States
Références
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Trends Cancer. 2017 Apr;3(4):253-258
pubmed: 28718437
BMC Res Notes. 2014 Dec 04;7:877
pubmed: 25475541
Br J Cancer. 2007 Dec 17;97(12):1696-700
pubmed: 18000505
Int J Cancer. 2009 Apr 1;124(7):1637-43
pubmed: 19089916
Am J Epidemiol. 2016 Dec 15;184(12):884-893
pubmed: 27923781
JAMA Oncol. 2017 Sep 1;3(9):1228-1236
pubmed: 28152151
Exp Hematol. 2007 Jun;35(6):939-46
pubmed: 17533048
J Urol. 2005 Feb;173(2):610-4
pubmed: 15643274
Int J Cancer. 2013 Dec 1;133(11):2672-80
pubmed: 23674344
Am J Epidemiol. 2013 Apr 1;177(7):617-24
pubmed: 23444102
Nat Genet. 2013 Apr;45(4):371-84, 384e1-2
pubmed: 23535731
Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2047-54
pubmed: 24019396
Nucleic Acids Res. 2009 Feb;37(3):e21
pubmed: 19129229
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):605-13
pubmed: 20142254
Int J Epidemiol. 2016 Oct;45(5):1634-1643
pubmed: 27498151
Cancer Res. 1999 Dec 1;59(23):5917-21
pubmed: 10606235
JAMA Oncol. 2017 May 1;3(5):636-651
pubmed: 28241208
Anticancer Res. 1998 May-Jun;18(3A):1345-9
pubmed: 9673338
Mutat Res. 1991 Mar-Nov;256(2-6):271-82
pubmed: 1722017
Oncogene. 2004 Jun 3;23(26):4505-15
pubmed: 15048073
Cancer Causes Control. 2011 Jul;22(7):1061-6
pubmed: 21643930
Int J Cancer. 2018 Jun 1;142(11):2234-2243
pubmed: 29318605
Oncotarget. 2017 Sep 23;8(56):95674-95691
pubmed: 29221158
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1152-6
pubmed: 19293310
Breast Cancer Res Treat. 2010 Apr;120(3):769-75
pubmed: 19543829
Nat Rev Genet. 2005 Aug;6(8):611-22
pubmed: 16136653
Trends Cell Biol. 2001 Nov;11(11):S27-31
pubmed: 11684439
Br J Cancer. 2015 Feb 17;112(4):769-76
pubmed: 25562437
Cancer Res. 2008 May 15;68(10):3618-23
pubmed: 18483243
Nurs Res. 2014 Jul-Aug;63(4):289-99
pubmed: 24977726
Nat Commun. 2013;4:1597
pubmed: 23511462
Hum Mol Genet. 2015 Sep 15;24(18):5356-66
pubmed: 26138067
Nutr Cancer. 2001;39(2):187-95
pubmed: 11759279
Cancer Res. 2010 Apr 15;70(8):3170-6
pubmed: 20395204
Cancer Res. 2014 Aug 1;74(15):4090-8
pubmed: 24853549
Front Oncol. 2012 Oct 04;2:135
pubmed: 23061048
Cancer Res. 2007 Jun 1;67(11):5538-44
pubmed: 17545637
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Aging (Albany NY). 2010 Nov;2(11):867-74
pubmed: 21113082
Physiol Rev. 2008 Apr;88(2):557-79
pubmed: 18391173
Eur J Cancer. 2009 Nov;45(17):3008-16
pubmed: 19766477
CA Cancer J Clin. 1982 Sep-Oct;32(5):301-13
pubmed: 6811109